Skip directly to content

Joint Working Project between Swansea University and Pfizer Ltd



As part of the U.K. government-funded £1.3bn City Deal, Swansea is seeking to become a UK hub for Life Sciences and Digital Innovation with the goal of creating interconnected eco-systems connecting academic, business, health and data spheres to cross-pollinate and sustain each other to improve patient outcomes and scale health innovation globally. Critical to enabling this vision and opportunity is the establishment of a Clinical-Digital center of excellence within the Swansea Health System. This capability is a shared objective of the stakeholder institutions in ARCH (a regional collaboration for health) and the Llanelli Health and Life Sciences Village Consortium.

Pfizer has an interest in digital healthcare solutions and aligns with Swansea’s plans to create a clinical-digital centre of excellence. Pfizer will formally collaborate with Swansea University; and the emergent Llanelli Health and Life Sciences Village Consortium on real-world research and innovation projects in the health and life science sector, which deliver against the vision of delivering improved wellbeing for the region’s population of approximately 1million people.

The overarching collaboration will:

  • Support the development of a system that better aligns industry, the NHS, and academia to innovating in the pursuit of improved patient and public outcomes;
  • Include optimising the unique Swansea Bay City Region Health, Wellbeing, and Life Science Ecosystem, which has a strong alignment to the UK Government’s Life Science Industrial Strategy and is often described as a ‘living laboratory’;
  • Demonstrate how many of the objectives of the Industrial Strategy can be operationalised within a region with purpose and pace, including potential partnering around City Deal proposals, including those with a strong community and primary care focus;
  • Lead a number of value-based healthcare pathfinder projects, with the specific aim of developing approaches that contribute to improved patient outcomes, assessed by considering quality alongside cost.  This will include a strong focus on digital healthcare delivery;
  • Capture the unique partnership propositions, approaches, and outcomes through presentations and publications that can be used within the UK and internationally.  This will include representing partnership activities with senior executive and political audiences;
  • Develop and or contribute to educational programmes, with the specific goal of delivering value based care through partnership.
  • Coordinate and lead structured experimentation aligning partnership stakeholders around a test and learn model for outcomes improvement solutions, ranging from patient education and activation activity to proactive and technology-enabled interventions, supported by milestone measurement and reporting.



This first project within this collaboration will be the creation of a 3 year Professor in Enhanced Health Innovation, Engagement and Outcomes post to coordinate and lead projects. This role will:

  • Create an environment that supports collaboration between Industry, NHS and Academia to deliver improved patient and population health outcomes.
  • Identify and lead projects that align with the Swansea Bay City Deal Health and Wellbeing strategy   

The Professor in Enhanced Health Innovation, Engagement and Outcomes will be supported by the creation of two further roles in the form of a Digital Technical Consultant and a Data Technician who both will support identification and implementation of projects identified through joint working.


Resource Input into Project

Pfizer will provide funding of £600k to support the recruitment of the Professor in Enhanced Health Innovation, Engagement and Outcomes role over the 3 year period.

Pfizer will provide funding of £50k each to support recruitment of the Data Technician role over a two year period.

Swansea University will provide funding of £150k to support recruitment of the Digital Technical Consultant role over the three year period.

Swansea University will provide funding of £50k each to support recruitment of the Data Technician role over a two year period.

Additional roles providing resources to support the joint working project:

  • Swansea University will provide a full time Project Support Officer, working 5 days per week over the 3 year period.
  • Pfizer will provide project delivery support from the Pfizer UK Strategic Accounts Team, working 4 days per week over the 3 year period.

In addition as part of the project, a two day ethnographic market research workshop is planned:

  • Swansea University will provide human resource and financial resource funding of £16.6k to support and deliver the outputs of the workshop.
  • Pfizer will provide funding of £24k for ethnographic market research to be carried out in order to understand the local resident experience; their general approach to managing their health and specific interest potential opportunities related to the Llanelli Health & Wellness Village.



Benefits to Patients:
  • Improved early stage education and risk awareness of disease
  • Improved activation, screening and detection of underlying conditions
  • Improved patient engagement, empowerment and control over their personal care journey (overall patient experience)
  • Access to preventative services including health, wellness, social and mental health interventions
  • Improved access to health, wellbeing and social care services, leading to increased speed of service attainment and easier navigation of a “one-stop shop environment”, that may improve attendance and convenience for patients, their care givers and their families
  • Participation in a culture of clinical research via an ethos that all patients are candidates for clinical studies
  • Improved active monitoring of condition progression, management and routine check-ups to optimise clinical and / or health system response
  • Continual adaptation of pathways and patient interventions to balance outcome improvement with patient control over living a full and positive life with their condition.
Benefits to Swansea

The set-up of the village creates a concentrated network of clinicians, healthcare professionals, academics and local authorities, presenting opportunity to:

  • Better generate better communication, idea sharing, efficiencies and creativity
  • Ensure a core digital infrastructure in which every interaction is captured, collected and utilized to drive continuous improvement in as near real-time a manner as possible
  • Rapidly develop transformative solutions by overcoming intrinsic barriers to experimentation in the current healthcare landscape locally and with compelling supporting evidence to effect system-wide change
  • Enhanced staff engagement in all partners, boosting productivity and ongoing skills development
  • Develop global leadership in value-based healthcare models, scalable to other systems in Wales, the UK and worldwide.


Benefits to Pfizer:
  • Demonstrate that by working with novel partners to convey health information to hard to reach or high risk population groups we can activate a broader, earlier and more effective patient response
  • Prove that Pfizer can partner with the healthcare system in the Swansea Bay City Region and employ novel technologies to help patients achieve real world outcomes from their medication equal to those achieved in a clinical trial setting
  • Where specific projects align with Pfizer therapy areas, potentially increase appropriate use of medicines, including Pfizer medicines,  in line with national guidelines
  • Establish Pfizer’s role in providing long term support to patients with chronic conditions to positively manage their health and lifestyle and sustain beneficial outcomes over time
  • By testing and learning in this unique healthcare system we will be able to adopt and scale innovation across regional and national populations
  • Enhance Pfizer’s reputation as a partner for healthcare innovation


PP-GIP-GBR-3758 / August 2018